Mainz Biomed N.V. Files Q2 2024 Financial Update
Ticker: MYNZ · Form: 6-K · Filed: Oct 18, 2024 · CIK: 1874252
| Field | Detail |
|---|---|
| Company | Mainz Biomed N.V. (MYNZ) |
| Form Type | 6-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, 6-K, disclosure
TL;DR
Mainz Biomed dropped its Q2 2024 financial report on Oct 18th.
AI Summary
On October 18, 2024, Mainz Biomed N.V. filed a Form 6-K to provide its Management's Discussion and Analysis of Financial Condition and Results of Operations for the six-month period ended June 30, 2024. This report details the company's financial performance and operational status during that period.
Why It Matters
This filing provides investors with a crucial update on Mainz Biomed's financial health and operational progress for the first half of 2024, aiding in investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing and does not contain new or significant risk-related information.
Key Players & Entities
- Mainz Biomed N.V. (company) — Registrant
- June 30, 2024 (date) — End of reporting period
- October 18, 2024 (date) — Filing date
FAQ
What type of report did Mainz Biomed N.V. file on October 18, 2024?
Mainz Biomed N.V. filed a Form 6-K containing its Management's Discussion and Analysis of Financial Condition and Results of Operations.
What period does the Management's Discussion and Analysis cover?
The report covers the six months ended June 30, 2024.
What is the Commission File Number for Mainz Biomed N.V.?
The Commission File Number is 001-41010.
Where is Mainz Biomed N.V. located?
Mainz Biomed N.V. is located at Robert Koch Strasse 50, 55129 Mainz, Germany.
Is Mainz Biomed N.V. required to file annual reports under Form 20-F?
Yes, Mainz Biomed N.V. indicated by a checkmark that it files annual reports under cover of Form 20-F.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 7.6 · Accepted 2024-10-18 16:00:40
Filing Documents
- ea0217811-6k_mainz.htm (6-K) — 22KB
- ea021781101ex99-1_mainz.htm (EX-99.1) — 87KB
- ea021781101ex99-2_mainz.htm (EX-99.2) — 690KB
- ea021781101ex99-3_mainz.htm (EX-99.3) — 11KB
- ea021781101ex99-4_mainz.htm (EX-99.4) — 22KB
- ea021781101ex99-5_mainz.htm (EX-99.5) — 24KB
- 0001213900-24-088934.txt ( ) — 5897KB
- mynz-20240630.xsd (EX-101.SCH) — 107KB
- mynz-20240630_cal.xml (EX-101.CAL) — 39KB
- mynz-20240630_def.xml (EX-101.DEF) — 331KB
- mynz-20240630_lab.xml (EX-101.LAB) — 646KB
- mynz-20240630_pre.xml (EX-101.PRE) — 350KB
- ea0217811-6k_mainz_htm.xml (XML) — 767KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the six months ended June 30, 2024 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant's name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events On October 18, 2024, Mainz Biomed N.V. made available its Management's Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2024. A copy of the report is attached hereto as Exhibit 99.1. On October 18, 2024, Mainz Biomed N.V. made available its unaudited Financial Statements for the six months ended June 30, 2024. A copy of the report is attached hereto as Exhibit 99.2. On or around October 23, 2024, Mainz Biomed N.V. will begin mailing to certain shareholders of record as of the close of business on October 16, 2024, a power of attorney and voting proxy card pursuant to Dutch law, relating to its extraordinary general meeting of shareholders to be held on November 13, 2024. Copies of certain of these documents are attached as Exhibits 99.3, 99.4, and 99.5 hereto. This current report on Form 6-K and exhibits 99.1, 99.2, 99.3, 99.4, and 99.5 hereto are hereby incorporated by reference into the Company's Registration Statement on Form F-3 (File No. 333-269091). Exhibit No. Exhibit 99.1 Management's Discussion and Analysis of Financial Condition and Results of Operations of Mainz Biomed N.V. for the six months ended June 30, 2024 99.2 Unaudited Financial Statements of Mainz Biomed N.V. as of and for the six months ended June 30, 2024 99.3 Notice of Annual General Meeting 99.4 Agenda of the Annual General Meeting 99.5 Voting Proxy Card, and Power of Attorney 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 18, 2024 By: /s/ William J. Caragol Name: William J. Caragol Title Chief Financial Officer 2